Frontiers in Psychiatry
January 21, 2020
Juan José Fuentes, Francina Fonseca, Matilde Elices et al.
176 citations
Lysergic acid diethylamide (LSD) was studied from the 1950s to the 1970s to evaluate behavioral and personality changes, as well as remission of psychiatric symptoms in various disorders. LSD was used in the treatment of anxiety, depression, psychosomatic diseases and addiction. However, most of the studies were not performed under contemporary standards, and it has taken several decades for a...
Journal of the History of Medicine and Allied Sciences
January 13, 2020
Michael Draper
1 citation
Psychedelics are back in vogue. In popular culture, political legislation, and scientific research, we appear to be witnessing an early twenty-first century renaissance of the heady acid days of the 1960s. The success of Michael Pollan’s 2018 New York Times bestseller, How to Change Your Mind, the decriminalization of psilocybin-containing mushrooms in Denver in 2019, followed by all plant...
International Journal of Advanced Psychiatric Nursing
2020
M. Baskaran, Saravanan Mani, T. Maheswari et al.
Lysergic acid diethylamide (LSD) is a semisynthetic compound with solid psychoactive properties. Chemically related to serotonin LSD was initially hypothesized to produce a psychosis-like state.1 Afterward, LSD was accounted for to have benefits in the treatment of addictions. However, far reaching unpredictable use and reports of unfriendly impacts brought about the arrangement of LSD as an...
History of Pharmacy and Pharmaceuticals
2020
Alexander S. Dawson
Patrick Wayne Barber, Psychedelic Revolutionaries: LSD and the Birth of Hallucinogenic Research. Regina: University of Regina Press, 2018; 384 pp; ISBN: 9780889774209; paper; $34.95. It seems a little odd to write this, but the history of psychedelic science in Saskatchewan is by now well-worn
Journal of Studies on Alcohol and Drugs
2020
Mark Haden, Birgitta Woods
31 citations
OBJECTIVE: In academic settings around the world, there is a resurgence of interest in using psychedelic substances for the treatment of addictions, posttraumatic stress disorder, depression, anxiety, and other diagnoses. This case series describes the medical consequences of accidental overdoses in three individuals. METHOD: Case series of information were gathered from interviews, health...
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
December 20, 2019
Anya K. Bershad, Katrin H. Preller, Royce Lee et al.
95 citations
BackgroundThe practice of "microdosing," or the use of repeated, very low doses of lysergic acid diethylamide (LSD) to improve mood or cognition, has received considerable public attention, but empirical studies are lacking. Controlled studies are needed to investigate both the therapeutic potential and the neurobiological underpinnings of this pharmacologic treatment.MethodsThe present study...
Psychopharmacology
December 18, 2019
Neiloufar Family, Émeline L. Maillet, Luke T. J. Williams et al.
142 citations
Abstract Abstract Research has shown that psychedelics, such as lysergic acid diethylamide (LSD), have profound anti-inflammatory properties mediated by 5-HT 2A receptor signaling, supporting their evaluation as a therapeutic for neuroinflammation associated with neurodegenerative disease. Objective This study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally...
bioRxiv (Cold Spring Harbor Laboratory)
December 6, 2019
Felipe Augusto Cini da Silva, Isis M. Ornelas, Encarni Marcos et al.
9 citations
preprint
Abstract Psychedelic agonists of serotonin receptors induce neural plasticity and synaptogenesis, but their potential to enhance learning remains uncharted. Here we show that a single dose of d-LSD, a potent serotonergic agonist, increased novel object preference in young and adult rats several days after treatment. d-LSD alone did not increase preference in old animals, but could rescue it to...
Neuropharmacology
November 19, 2019
Adam L. Halberstadt, Muhammad Chatha, Adam K. Klein et al.
37 citations
The ergoline d-lysergic acid diethylamide (LSD) is one of the most potent psychedelic drugs. 1-Acetyl-LSD (ALD-52), a derivative of LSD containing an acetyl group on the indole nitrogen, also produces psychedelic effects in humans and has about the same potency as LSD. Recently, several other 1-acyl-substitued LSD derivatives, including 1-propanoyl-LSD (1P-LSD) and 1-butanoyl-LSD (1B-LSD), have...
Neuropsychopharmacology
November 16, 2019
Friederike Holze, Patrick Vizeli, Felix Müller et al.
250 citations
Abstract Lysergic acid diethylamide (LSD) is a classic psychedelic, 3,4-methylenedioxymethamphetamine (MDMA) is an empathogen, and d -amphetamine is a classic stimulant. All three substances are used recreationally. LSD and MDMA are being investigated as medications to assist psychotherapy, and d -amphetamine is used for the treatment of attention-deficit/hyperactivity disorder. All three...